JAB-3312 |
JAB-3312 |
Phase 3 Clinical |
Jacobio Pharmaceuticals Co Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
JAB-3068 |
JAB-3068 |
Phase 2 Clinical |
Jacobio Pharmaceuticals Co Ltd, Abbvie Inc |
Solid tumours; Head and Neck Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Adenoid Cystic; Esophageal Squamous Cell Carcinoma; Lymphoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Vociprotafib |
RMC-4630; SAR-442720 |
Phase 2 Clinical |
Sanofi, Revolution Medicines Inc |
Solid tumours; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Details
|
TNO-155 |
TNO-155 |
Phase 2 Clinical |
Novartis Pharma Ag |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Renal Insufficiency; Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Hepatic Insufficiency; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma |
Details
|
GH-21 |
GH 21005; GH-21; HBI-2376 |
Phase 2 Clinical |
Suzhou GenHouse pharmaceutical Co Ltd |
Solid tumours; Head and Neck Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
BR-790 |
BR-790 |
Phase 2 Clinical |
Jiangxi Qingfeng Pharmaceutical Industry Co Ltd |
Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
BBP-398 |
IACS-15509; BBP-398; IACS-13909; BMS-986466 |
Phase 2 Clinical |
Bridgebio Pharma Inc, The University Of Texas MD Anderson Cancer Center |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
Migoprotafib |
RLY-1971; GDC-1971; RO-7517834; RG-6433 |
Phase 1 Clinical |
Relay Therapeutics Inc |
Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
A-380 |
A-380 |
Phase 1 Clinical |
Shandong Kelun Phaemaceutical Co Ltd, Klus Pharma Inc |
Neoplasms |
Details
|
RG-001 |
RG001; RG-001 |
Phase 1 Clinical |
Shanghai Lingji Biological Technology Co Ltd |
Neoplasms |
Details
|
HMPL-415S1 |
HMPL-415S1 |
Phase 1 Clinical |
Hutchison Medipharma Ltd |
Solid tumours |
Details
|
BPI-442096 |
|
Phase 1 Clinical |
Betta Pharmaceuticals Co Ltd |
Solid tumours; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
HS-10381 |
HS-10381 |
Phase 1 Clinical |
Jiangsu Hansoh Pharmaceutical Group Co Ltd |
Solid tumours |
Details
|
ET-0038 |
ET-0038 |
Phase 1 Clinical |
Shanghai Yituo Pharmaceutical Technology Co Ltd |
Solid tumours |
Details
|
PF-07284892 |
ARRY-558; PF-07284892 |
Phase 1 Clinical |
Pfizer Inc |
Solid tumours; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung |
Details
|
ICP-189 |
ICP-189 |
Phase 1 Clinical |
InnoCare Pharma Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
ERAS-601 |
ERAS-601 |
Phase 1 Clinical |
Erasca Inc |
Solid tumours; Leukemia, Myeloid, Acute |
Details
|
SH-3809 |
SH3809 |
Phase 1 Clinical |
Nanjing Sanhome Pharmaceutical Co Ltd |
Solid tumours |
Details
|